A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 550 shares of EDIT stock, worth $1,342. This represents 0.0% of its overall portfolio holdings.

Number of Shares
550
Previous 500 10.0%
Holding current value
$1,342
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.39 - $5.96 $169 - $298
50 Added 10.0%
550 $1,000
Q1 2024

May 15, 2024

BUY
$7.03 - $11.07 $3,515 - $5,535
500 New
500 $3.71 Million
Q3 2022

Aug 14, 2024

SELL
$12.16 - $19.42 $3,648 - $5,826
-300 Reduced 30.0%
700 $8.57 Million
Q2 2022

Aug 14, 2024

SELL
$9.99 - $21.35 $999 - $2,135
-100 Reduced 9.09%
1,000 $11.8 Million
Q1 2022

Aug 14, 2024

BUY
$14.08 - $27.63 $8,448 - $16,578
600 Added 120.0%
1,100 $20.9 Million
Q4 2021

Aug 30, 2024

SELL
$26.55 - $40.57 $5,310 - $8,114
-200 Reduced 15.38%
1,100 $29.2 Million
Q3 2021

Aug 30, 2024

BUY
$39.27 - $72.94 $1,963 - $3,647
50 Added 4.0%
1,300 $53.4 Million
Q2 2021

Aug 30, 2024

BUY
$31.29 - $56.64 $23,467 - $42,480
750 Added 150.0%
1,250 $70.8 Million
Q1 2021

Aug 30, 2024

BUY
$39.71 - $90.58 $22,436 - $51,177
565 Added 55.39%
1,585 $66.6 Million
Q4 2020

Aug 30, 2024

BUY
$27.07 - $84.35 $22,197 - $69,167
820 Added 410.0%
1,020 $71.5 Million
Q3 2020

Aug 30, 2024

SELL
$28.06 - $37.16 $2,806 - $3,715
-100 Reduced 33.33%
200 $5.61 Million
Q4 2019

Aug 30, 2024

BUY
$19.49 - $32.63 $1,948 - $3,263
100 Added 50.0%
300 $8.88 Million
Q2 2019

Aug 30, 2024

SELL
$20.48 - $27.76 $6,144 - $8,328
-300 Reduced 60.0%
200 $4.95 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.